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Abstract
Introduction Inflammatory stimuli are causative for insulin
resistance in obesity as well as in acute inflammatory reactions.
Ongoing research has identified a variety of secreted proteins
that are released from immune cells and adipocytes as
mediators of insulin resistance; however, knowledge about their
relevance for acute inflammatory insulin resistance remains
limited. In this study we aimed for a clarification of the relevance
of different insulin resistance mediating factors in an acute
inflammatory situation.
Methods Insulin resistance was measured in a cohort of 37 non-
diabetic patients undergoing cardiac surgery by assessment of
insulin requirement to maintain euglycaemia and repeated
measurements of an insulin glycaemic index. The kinetics of
cortisol, interleukin 6 (IL6), tumour necrosis factor  (TNF),
resistin, leptin and adiponectin were assessed by repeated
measurements in a period of 48 h.
Results Insulin resistance increased during the observation
period and peaked 22 h after the beginning of the operation. IL6
and TNF displayed an early increase with peak concentrations
at the 4-h time point. Serum levels of cortisol, resistin and leptin
increased more slowly and peaked at the 22-h time point, while
adiponectin declined, reaching a base at the 22-h time point.
Model assessment identified cortisol as the best predictor of
insulin resistance, followed by IL6, leptin and adiponectin. No
additional information was gained by modelling for TNF,
resistin, catecholamine infusion rate, sex, age, body mass index
(BMI), operation time or medication.
Conclusions Serum cortisol levels are the best predictor for
inflammatory insulin resistance followed by IL6, leptin and
adiponectin. TNF, and resistin have minor relevance as
predictors of stress dependent insulin resistance.
Introduction
The Western lifestyle has created a pandemic of obesity,
which has dramatically increased the prevalence of insulin
resistance and diabetes mellitus. Efforts to understand the
linkage between the accumulation of body fat and the occur-
rence of insulin resistance have identified a variety of adipose
tissue derived secreted proteins as mediators for insulin resist-
ance. Some of these so-called adipokines such as leptin or
adiponectin are adipocyte specific, while other mainly inflam-
matory cytokines are secreted by immune cells that infiltrate
the adipose tissue in an obesity dependent manner. Diabetes
has therefore also been considered a chronic inflammatory
disease [1]. The relevance of inflammatory proteins as media-
tors of insulin resistance is not restricted to the chronic meta-
bolic environment of obesity but also found in acute
inflammatory reactions such as sepsis, which are marked by
severe insulin resistance and often hyperglycaemia. Inflamma-
tory cytokines such as tumour necrosis factor (TNF) and
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interleukin (IL)6 activate signalling cascades including nuclear
factor B (NF-B) and C-Jun N-terminal kinases (JNK), which
inhibit insulin signalling by serine phosphorylation of insulin
receptor substrate 1 (IRS-1) and thereby reduce translocation
of the glucose transporter GLUT4 to the cell membrane [1].
Adipocyte specific regulators of insulin sensitivity include lep-
tin, which primarily serves as a fuel storage sensor relevant for
appetite regulation and thermogenesis [2]. Adiponectin, which
promotes insulin sensitivity by activation of adenosine mono-
phosphate-activated protein kinase (AMPK) and resistin,
which has been identified as an adipocyte specific promoter of
insulin resistance in mice [3].
While these factors were characterised in the chronic meta-
bolic environment of obesity, our knowledge about their rele-
vance as mediators of insulin resistance in acute inflammatory
situations remains limited. Stress induced insulin resistance
has classically been ascribed to increased serum levels of cor-
tisol which promotes gluconeogenesis and inhibits peripheral
glucose disposal in a stress dependent manner. However,
TNF, IL6, resistin or leptin are induced and adiponectin levels
are reduced by inflammatory stimuli, which makes it likely that
similar mechanisms are relevant in chronic and acute inflam-
mation [4,5]. The comparable pattern of regulative proteins in
the chronic environment of obesity and in acute inflammation
suggests similar causative mechanisms of insulin resistance.
Identification and characterisation of the most important path-
ways of insulin resistance remains crucial for the development
of new therapeutic strategies. The relevance of tight glycaemic
control is thereby not restricted to the treatment of diabetes
but also crucial in acute inflammatory situations, where main-
tenance of euglycaemia improved perioperative outcome and
reduced mortality in critically ill patients [6,7]. While obesity is
a relative static cause of insulin resistance, characterised by
low grade inflammation, we here decided to study the time
course of insulin resistance following the acute intervention of
cardiac surgery with extracorporeal circulation, which is a
known inflammatory stimulus [8,9]. The aim of the current
study was to classify the relevance of different insulin resist-
ance mediating factors in direct comparison to each other.
Materials and methods
We prospectively enrolled 37 non-diabetic patients scheduled
for cardiac surgery with cardiopulmonary bypass and require-
ment of extracorporeal circulation. Patients were excluded
from the study if they met the following criteria: pregnancy, dia-
betes mellitus, fasting glucose > 126 mg/dl, use of antidia-
betic medication or glucocorticoids.
Patients were fasting since the evening of the preoperative
day. Insulin resistance was recorded by the individual insulin
requirements to maintain euglycaemia. Blood glucose was
assessed on an hourly bases and insulin infusion rate conse-
quently adjusted to maintain glucose levels between 80 and
126 mg/dl. In addition, repeated measurements of C peptide
as an indicator of endogenous insulin production were
recorded as well as insulin serum levels, representing the cir-
culating sum of endogenously produced and exogenous
applied insulin. An insulin glycaemic index was calculated at
each time point (insulin × glucose/22.5). Blood samples were
drawn directly before surgery (baseline), at arrival in the inten-
sive care unit (ICU) (4 to 6 h time point), 6 h post arrival in the
ICU (10 to 12 h time point) and the morning of the first and
second postoperative days. As some patients were dis-
charged to a normal ward at the first postoperative day, blood
was only collected from 26 patients on the second postoper-
ative day. Blood samples were stored on ice and directly cen-
trifuged for serum collection. No glucose containing solutions
were given during the day of the procedure, while all patients
were started on a continuous infusion of glucose 10% with a
rate of 10 ml/h at the morning of the first postoperative day.
Low rate exogenous applied glucose did therefore only affect
the last blood sampling at the second postoperative day. No
additional parenteral or enteral nutrition was supplied during
the observation period. The applied catecholamine doses
were recorded at the blood collection time point in mg/h. The
study protocol was approved by the Ethics Committee of the
Ludwig-Maximilians-University Munich, Germany. All patients
gave informed written consent.
Laboratory procedures
Blood samples were stored at -70°C until analysis. Serum lev-
els of TNF, IL6, leptin, adiponectin and resistin were deter-
mined with a commercial enzyme-linked immunosorbent assay
(R&D, Wiesbaden, Germany). Serum concentrations of corti-
sol, insulin, and C peptide were quantified using a multichan-
nel immunoanalyzer based on electrochemiluminescence as
the principle of signal generation (Roche Cobas, Elecsys
2010; Roche Diagnostics Mannheim, Germany) by the
Department of Clinical Chemistry (Campus Grosshadern, Uni-
versity of Munich, Germany).
Statistical analysis
Spearman correlation was performed for associations
between baseline characteristics. A linear mixed effects model
was fit to model the influence of the metabolic factors on insu-
lin resistance (log insulin glycaemic index). The factors were
included forward by a likelihood ratio test. A random effect per
patient accounts for the subjective level of each patient (which
includes the baseline levels) and for the dependence of the
measurements within each patient. All measurements of a
patient were used together with the time after surgery when
they occurred (rounded to the nearest hour) Curves were fit-
ted by the non-parametric locally-weighted scatterplot
smoothing (LOWESS) smoother, which uses locally-weighted
polynomial regression. Statistical analysis was performed
using R 2.6.1.Available online http://ccforum.com/content/12/6/R157
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Results
Baseline characteristics of the study participants are shown in
Table 1. All patients underwent open cardiac surgery with car-
diopulmonary bypass.
Kinetics of insulin resistance
Blood glucose was monitored on an hourly basis throughout
the observation period. All patients required insulin treatment
to maintain euglycaemia. Consequently, blood glucose was
kept stable throughout the observation period (Figure 1a),
while insulin infusion rate increased with maximum concentra-
tions required between the 17th and 38th hour of observation
(Figure 1b), while required catecholamine doses declined
throughout the observation period (Figure 1c). Blood samples
were drawn at baseline, early postoperative, directly after sub-
mission to the ICU (marking a 4 to 6 h time point), 6 h after
submission to the ICU (marking the 10 to 12 h time point) and
the morning of the first and second postoperative days. C Pep-
tide concentrations declined during the observation period,
reaching a base at the 22 h time point, signifying a suppres-
sion of endogenous insulin production by exogenously applied
insulin (Figure 1d). Serum insulin concentrations increased
during the first 22 h of observation, following the course of
exogenously applied insulin and remained stable thereafter
(Figure 1e). To create a more specific parameter of insulin
resistance that combines serum glucose with serum insulin
levels, we decided to calculate an insulin glycaemic index
(insulin × glucose/22.5) at each time point (Figure 1f). Conse-
quently, the insulin glycaemic index increased during the first
22 h of the observation period and remained stable thereafter,
again resembling the kinetics of exogenous applied insulin.
Baseline characteristics of serum parameters
At baseline (preoperative blood sample) we found correlations
between IL6, resistin and TNF (IL6-resistin; r = 0.4; p < 0.01)
(IL6-TNF; r = 0.29; p < 0.05) (resistin-TNF; r = 0.33; p <
0.05). In addition, baseline leptin and adiponectin were found
to correlate positively or negatively with body mass index (BMI)
(leptin-BMI; r = 0.5; p < 0.001) (adiponectin-BMI; r = -0.45; p
< 0.01).
Inflammatory kinetic of serum parameters
During the observation period inflammatory cytokines rapidly
increased with peak concentrations of TNF and IL6 found at
the 4 to 6 h time point (Figure 2a,b). Serum levels of leptin ini-
tially decreased, reaching a minimum at the 10 to 12 h time
point to secondarily increase to supranormal levels peaking at
the 20 to 22 h time point (Figure 2c). Adiponectin serum levels
were repressed throughout the observation period reaching a
minimum at the 20 to 22 h time point (Figure 2d). Resistin
serum levels steadily increased to reach their maximum at the
20 to 22 h time point (Figure 2e). Cortisol serum levels
increased during the observation period with maximum con-
centrations found at the 20 to 22 h time point (Figure 2f).
Prediction of insulin resistance by serum parameters
We next asked which parameter would best predict insulin
resistance. Using a linear mixed effects model we included the
parameters by a forward selection using a likelihood ratio test
to predict the individual insulin resistance as measured by the
insulin glycaemic index. The model thereby includes the base-
line and all following values of each parameter in a time
dependent manner for each patient. The kinetic of each param-
eter was than analyzed for its relevance to predict insulin
resistance in the same patient.
Table 1
Baseline characteristics of the study population.
Characteristics n = 37
Age (years) 69 (60 to 74)
Sex:
Male 23
Female 14
Body mass index (kg/m2) 27.1 (23.1 to 29.9)
Hypertension 72%
Smoker (yes) 31%
Baseline laboratory profile:
Glucose (mg/dl) 99 (91 to 107)
Insulin (uU/ml) 4.25 (1.9 to 6.7)
insulin glycaemic index 1.03 (0.45 to 1.77)
C Peptide (ng/ml) 1.6 (1.2 to 2.3)
Cortisol (ug/dl) 12.3 (7.4 to 16.1)
IL6 (pg/ml) 2 (2.0 to 2.45)
TNF (pg/ml) 8.07 (6.37 to 19.14)
Resistin (ng/ml) 10.44 (7.94 to 14.5)
Leptin (pg/ml) 4,752 (2,714 to 10,636)
Adiponectin (ng/ml) 4,227 (2,917 to 7,190)
Medical treatment:
Statin 67%
Beta blocker 78%
ACE-I or ARB 47%
Diuretics 56%
Aspirin 100%
Intervention:
Operation time (min) 300 (270 to 330)
Heart/lung bypass time (min) 89 (74 to 106)
Values are presented as median (interquartile range) or proportions. 
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; Il, interleukin; TNF, tumour necrosis factor.Critical Care    Vol 12 No 6    Lehrke et al.
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Serum cortisol was found to be the strongest predictor for the
insulin glycaemic index (F = 104.26; p < 0.0001), followed by
IL6 (F = 27.63; p < 0.0001), leptin (F = 18.12; p < 0.0001)
and adiponectin (F = 4.7; p < 0.05) (Table 2). Additional mod-
elling for TNF, resistin, catecholamine infusion rate, age, gen-
der, BMI, operation time, heart/lung bypass time or medication
did not further improve the model, suggesting minor contribu-
tion of these parameters to the development of insulin resist-
ance in our model.
Discussion
To better understand the relevance of different mediators of
insulin resistance we have performed kinetic studies in an
acute inflammatory setting in humans. Inflammation caused by
cardiac surgery increased insulin resistance in a time depend-
Figure 1
Kinetics of insulin resistance Kinetics of insulin resistance. Shown is the kinetic of serum glucose (a) and insulin infusion rate (b) during the observation period depicted as 
mean ± standard error of the mean (SEM). In addition, log (catecholamine infusion rate+1) (c), serum levels of log C peptide (d), and log insulin (e) 
log insulin glycaemic index (f) are depicted as a scatter plot with its locally-weighted scatterplot smoothing (LOWESS) estimation curve. The log 
scale was chosen for better presentation of outliers.Available online http://ccforum.com/content/12/6/R157
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ent manner which was paralleled by an induction of cortisol,
TNF, IL6, resistin and leptin while adiponectin serum levels
were decreased. Testing the relevance of each parameter to
predict insulin resistance we found best performance for
serum cortisol followed by serum IL6, leptin and adiponectin.
No additional information was gained by modelling for TNF,
resistin, catecholamine infusion rate, gender, BMI, operation
time, heart/lung bypass time or medication, suggesting a
minor relevance of these parameters for inflammatory insulin
resistance in our model.
Cortisol is the major adaptive signalling regulator of stress.
Cortisol increases glucose availability by augmentation of
hepatic glucose production via transcriptional and post-tran-
scriptional activation of gluconeogenic enzymes including glu-
cose-6-phosphatase and phosphoenolpyruvate [10]. In
addition, cortisol inhibits glucose uptake and utilisation by
peripheral tissues [11]. By contrast, cortisol excess impairs
glucose tolerance and causes diabetes. Our model therefore
confirms the dominating role of cortisol as a regulator of stress
dependent insulin resistance.
Figure 2
Kinetics of serum parameters Kinetics of serum parameters. Shown is the kinetic of serum log tumour necrosis factor (TNF) (a), log interleukin (IL)6 (b), log leptin (c), log adi-
ponectin (d), log resistin (e) and log cortisol (f) during the observation period depicted as a scatter plot with its locally-weighted scatterplot smooth-
ing (LOWESS) estimation curve. The log scale was chosen for better presentation of outliers.Critical Care    Vol 12 No 6    Lehrke et al.
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An ongoing debate considers the relevance of IL6 as a medi-
ator of insulin resistance in humans [12,13]. Initial evidence for
a functional interplay was created by increased serum levels of
IL6 in obesity in which IL6 was found to be associated with
insulin resistance [14-17]. Interventional studies, using acute
or chronic application of IL6, confirmed its potential to induce
insulin resistance [18,19], while antibody-neutralisation exper-
iments of IL6 were found to do the opposite [20]. Mechanisti-
cally, IL6 was found to impair insulin signalling primarily in the
liver by induction of suppressor of cytokine signalling 3
(SOCS3) and inhibitory IRS-1 phophorylation [21]. However,
application of IL6 to healthy volunteers recently failed to cause
insulin resistance in humans [22] and was even associated
with improved muscular glucose disposal and decreased
endogenous glucose production, which was attributed to IL6
dependent activation of AMPK [21]. These studies were how-
ever limited by a confined observation period of a maximum 3
h, which was probably not sufficient to detect deleterious
effects of IL6 on insulin sensitivity. Our study argues for a rel-
evant role of IL6 as a mediator of stress dependent insulin
resistance in the acute inflammatory setting in humans.
Leptin is a predominant regulator of energy metabolism with
additional immune regulatory functions [23]. Leptin secretion
is increased by inflammatory stimuli and promotes cellular and
humoural immune responses. Leptin thereby stimulates the
secretion of TNF and IL6 from mononuclear cells and orches-
trates in the cytokine network of inflammation [24]. Consist-
ently, leptin deficiency impairs immune function, making the
hosts more vulnerable to infectious disease [25,26]. Reports
of leptin dependent effects on insulin sensitivity have been
conflicting [27]. In a variety of studies, leptin administration
was found to improve insulin sensitivity independently of body
weight reducing effects [28,29]. However, other studies found
no effect of leptin on glucose homeostasis [30], while addi-
tional studies reported leptin dependent inhibition of insulin
secretion [31] and insulin signalling in isolated hepatocytes,
myocytes or adipocytes [27]. Interestingly, leptin levels were
suppressed at early time points in our model but secondarily
increased to suprabasal levels at later time points and overall
positively associated with insulin resistance. These results
suggest a contributive effect of leptin to insulin resistance in
inflammatory settings. Alternatively, our observations could
also signify the occurrence of inflammation dependent leptin
resistance, provoking a contra regulatory increase of leptin
secretion [32]. Future studies are needed to clarify the rele-
vance of inflammation dependent leptin secretion for insulin
resistance.
Adiponectin has been identified as an insulin sensitising adi-
pocyte derived protein, which is decreased in obesity [3]. Adi-
ponectin deficient mice are prone to diet induced obesity and
insulin resistance, which can be reversed by adiponectin treat-
ment [33]. In humans low adiponectin was found to be closer
associated with insulin resistance than adiposity [34]. Con-
sistent with others we found inflammation dependent repres-
sion of adiponectin serum levels in our model which was
modestly associated with insulin resistance, suggesting a con-
tribution of adiponectin reduction to stress dependent insulin
resistance [4]. The inflammatory regulation of adiponectin and
leptin and their association to glucose metabolism in our
model suggests a direct contribution of the adipose tissue to
stress dependent glucose metabolism. Although, these adi-
pocyte derived signals are presumably less relevant than cor-
tisol as major metabolic adaptor to stress.
Resistin has been established as an adipocyte derived media-
tor of insulin resistance in mice [35]. Some but not all studies
found a similar functional role in humans [3]. In contrast to
mice, resistin is expressed by mononuclear cells in humans
and stimulated in an inflammation dependent manner [36].
This prompted the hypothesis of resistin being a prominent
mediator of inflammatory insulin resistance in humans, which
we could not confirm in this study.
Although TNF has been found to be a mediator of insulin
resistance in acute and chronic models of inflammation
[22,37], TNF was not identified as an influential mediator in
our model. This discrepancy could be explained by indirect
effects of TNF on insulin resistance, potentially requiring the
Table 2
Prediction of insulin glycaemic index by different serum parameters using the equation: E(log(Homaij)|bi) = 0 + 1 log(Corti)ij + 2 
log(Il6)ij + 3 log(lep)ij + 4 log(adi)ij + bi, i = 1,..., 37, j = 1,..., 5 Where i indicates patients 1 to 37 and j indicates the different time 
points (1 to 5) assessed in each patient
 Estimate, confidence interval F value p Value
Intercept 0 -1.25 (-4.10 to 1.60) 84.75 < 0.0001
Log cortisol 1 0.57 (0.43 to 0.71) 104.26 < 0.0001
Log IL6 2 0.20 (0.12 to 0.28) 27.63 < 0.0001
Log leptin 3 0.29 (0.15 to 0.43) 18.12 < 0.0001
Log adiponectin 4 -0.37 (-0.64 to -0.03) 4.7 0.03
The likelihood ratio test was used to model for insulin glycaemic index. IL, interleukin.Available online http://ccforum.com/content/12/6/R157
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induction of an additional TNF dependent mediator of insulin
resistance such as cortisol [38].
Better understanding of the relevant mediators of inflammatory
insulin resistance will provide potentially clinical relevant infor-
mation. Following the concept of relative adrenal insufficiency
substitution of hydrocortisone has widely been used in criti-
cally ill patients. A recent study has now re-evaluated this
approach and reported minor survival rates in hydrocortisone
treated patients with septic shock due to infectious causes
[39]. Taking the beneficial effects of normoglycaemia in the
same patient collective, induction of cortisol dependent insulin
resistance and hyperglycaemia might contribute to the
observed detrimental effects [6,7].
This study has several limitations. We used an insulin glycae-
mic index to quantify insulin resistance, which is less precise
than an insulinic clamp, the gold standard for the assessment
of insulin resistance. However, the extended observation
period limited the use of a clamp setting in our study. Future
experiments are needed to confirm our results under clamp
conditions.
The proposed model only offers associations but cannot pro-
vide causal relationship between the different parameters and
insulin resistance. In addition, we cannot role out that other
mediators of insulin resistance such as catecholamines, gluca-
gon or growth hormone might also have contributive effects.
The study is further limited by a relatively small sample size.
Further studies in larger cohorts are needed to confirm the
obtained results and further differentiate the relevance of spe-
cific factors preferentially under insulinic clamp conditions.
Conclusion
Serum cortisol levels are the best predictor for inflammatory
insulin resistance followed by IL6, leptin and adiponectin.
TNF, and resistin have minor relevance as predictors of
stress dependent insulin resistance.
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